Chromosome segregation errors: a double-edged sword - TI Pharma

&
511. Andreassen, P.R., et al., Tetraploid state induces p53-dependent arrest of nontransformed mammalian cells in G1.
Mol Biol Cell, 2001. 12(5): p. 1315-28.
512. Ganem, N.J. and D. Pellman, Limiting the proliferation of polyploid cells. Cell, 2007. 131(3): p. 437-40.
513. Doxsey, S., Re-evaluating centrosome function. Nat Rev Mol Cell Biol, 2001. 2(9): p. 688-98.
514. Mazumdar, M., et al., Tumor formation via loss of a molecular motor protein. Curr Biol, 2006. 16(15): p. 1559-64.
515. Olaharski, A.J., et al., Tetraploidy and chromosomal instability are early events during cervical carcinogenesis.
Carcinogenesis, 2006. 27(2): p. 337-43.
516. Galipeau, P.C., et al., 17p (p53) allelic losses, 4N (G2/tetraploid) populations, and progression to aneuploidy in
Barrett’s esophagus. Proc Natl Acad Sci U S A, 1996. 93(14): p. 7081-4.
517. D’Assoro, A.B., et al., Amplified centrosomes in breast cancer: a potential indicator of tumor aggressiveness. Breast
Cancer Res Treat, 2002. 75(1): p. 25-34.
518. D’Assoro, A.B., W.L. Lingle, and J.L. Salisbury, Centrosome amplification and the development of cancer. Oncogene,
2002. 21(40): p. 6146-53.
519. Basto, R., et al., Centrosome amplification can initiate tumorigenesis in flies. Cell, 2008. 133(6): p. 1032-42.
520. Meraldi, P., R. Honda, and E.A. Nigg, Aurora-A overexpression reveals tetraploidization as a major route to
centrosome amplification in p53-/- cells. EMBO J, 2002. 21(4): p. 483-92.
521. Fukasawa, K., Oncogenes and tumour suppressors take on centrosomes. Nat Rev Cancer, 2007. 7(12): p. 911-24.
522. Khodjakov, A., et al., De novo formation of centrosomes in vertebrate cells arrested during S phase. J Cell Biol, 2002.
158(7): p. 1171-81.
523. Uetake, Y., et al., Cell cycle progression and de novo centriole assembly after centrosomal removal in untransformed
human cells. J Cell Biol, 2007. 176(2): p. 173-82.
524. Ring, D., R. Hubble, and M. Kirschner, Mitosis in a cell with multiple centrioles. J Cell Biol, 1982. 94(3): p. 549-56.
525. Quintyne, N.J., et al., Spindle multipolarity is prevented by centrosomal clustering. Science, 2005. 307(5706): p. 127-
9.
526. Brinkley, B.R., Managing the centrosome numbers game: from chaos to stability in cancer cell division. Trends Cell
Biol, 2001. 11(1): p. 18-21.
527. Kwon, M., et al., Mechanisms to suppress multipolar divisions in cancer cells with extra centrosomes. Genes Dev,
2008. 22(16): p. 2189-203.
528. Yuen, K.W., B. Montpetit, and P. Hieter, The kinetochore and cancer: what’s the connection? Curr Opin Cell Biol, 2005.
17(6): p. 576-82.
529. Thompson, S.L., S.F. Bakhoum, and D.A. Compton, Mechanisms of chromosomal instability. Curr Biol, 2010. 20(6): p.
R285-95.
530. Schvartzman, J.M., R. Sotillo, and R. Benezra, Mitotic chromosomal instability and cancer: mouse modelling of the
human disease. Nat Rev Cancer, 2010. 10(2): p. 102-15.
531. Duesberg, P., et al., Aneuploidy precedes and segregates with chemical carcinogenesis. Cancer Genet Cytogenet,
2000. 119(2): p. 83-93.
532. Holland, A.J. and D.W. Cleveland, Boveri revisited: chromosomal instability, aneuploidy and tumorigenesis. Nat Rev
Mol Cell Biol, 2009. 10(7): p. 478-87.
533. Schmidt, M. and R.H. Medema, Exploiting the compromised spindle assembly checkpoint function of tumor cells:
dawn on the horizon? Cell Cycle, 2006. 5(2): p. 159-63.
534. Torres, E.M., B.R. Williams, and A. Amon, Aneuploidy: cells losing their balance. Genetics, 2008. 179(2): p. 737-46.
535. Cohen, J., Sorting out chromosome errors. Science, 2002. 296(5576): p. 2164-6.
536. Vitale, I., et al., Chk1 inhibition activates p53 through p38 MAPK in tetraploid cancer cells. Cell Cycle, 2008. 7(13): p.
1956-61.
537. Guo, Z., et al., ATM activation by oxidative stress. Science, 2010. 330(6003): p. 517-21.
538. Torres, E.M., et al., Identification of aneuploidy-tolerating mutations. Cell, 2010. 143(1): p. 71-83.
539. Yang, Z., et al., Extra centrosomes and/or chromosomes prolong mitosis in human cells. Nat Cell Biol, 2008. 10(6): p.
748-51.
540. Buffin, E., D. Emre, and R.E. Karess, Flies without a spindle checkpoint. Nat Cell Biol, 2007. 9(5): p. 565-72.
541. Godinho, S.A., M. Kwon, and D. Pellman, Centrosomes and cancer: how cancer cells divide with too many
centrosomes. Cancer Metastasis Rev, 2009. 28(1-2): p. 85-98.
542. Cox, C.D., et al., Kinesin spindle protein (KSP) inhibitors. 9. Discovery of (2S)-4-(2,5-difluorophenyl)-n-[(3R,4S)-3-fluoro-
1-methylpiperidin-4-yl]-2- (hydroxymethyl)-N-methyl-2-phenyl-2,5-dihydro-1H-pyrrole-1-carboxamide (MK-0731) for
the treatment of taxane-refractory cancer. J Med Chem, 2008. 51(14): p. 4239-52.
543. Sakowicz, R., et al., Antitumor activity of a kinesin inhibitor. Cancer Res, 2004. 64(9): p. 3276-80.
544. Gumireddy, K., et al., ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent.
Cancer Cell, 2005. 7(3): p. 275-86.
545. Steegmaier, M., et al., BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo.
Curr Biol, 2007. 17(4): p. 316-22.
546. Schoffski, P., Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology. Oncologist,
2009. 14(6): p. 559-70.
547. Degenhardt, Y. and T. Lampkin, Targeting Polo-like kinase in cancer therapy. Clin Cancer Res, 2010. 16(2): p. 384-9.
548. LeRoy, P.J., et al., Localization of human TACC3 to mitotic spindles is mediated by phosphorylation on Ser558 by
Aurora A: a novel pharmacodynamic method for measuring Aurora A activity. Cancer Res, 2007. 67(11): p. 5362-70.
549. Kitzen, J.J., M.J. de Jonge, and J. Verweij, Aurora kinase inhibitors. Crit Rev Oncol Hematol, 2010. 73(2): p. 99-110.
550. Santaguida, S., et al., Dissecting the role of MPS1 in chromosome biorientation and the spindle checkpoint through
the small molecule inhibitor reversine. J Cell Biol, 2010. 190(1): p. 73-87.
551. Heim, S.a.M., F., Cancer Cytogenetics1995: Wiley Liss Inc., New York.
552. Horwitz, S.B., Taxol (paclitaxel): mechanisms of action. Ann Oncol, 1994. 5 Suppl 6: p. S3-6.
553. Brito, D.A. and C.L. Rieder, The ability to survive mitosis in the presence of microtubule poisons differs significantly
between human nontransformed (RPE-1) and cancer (U2OS, HeLa) cells. Cell Motil Cytoskeleton, 2008.
554. Ikui, A.E., et al., Low concentrations of taxol cause mitotic delay followed by premature dissociation of p55CDC from
Mad2 and BubR1 and abrogation of the spindle checkpoint, leading to aneuploidy. Cell Cycle, 2005. 4(10): p. 1385-8.
555. Chen, J.G. and S.B. Horwitz, Differential mitotic responses to microtubule-stabilizing and -destabilizing drugs. Cancer
Res, 2002. 62(7): p. 1935-8.
556. Fu, Y., et al., Weakened spindle checkpoint with reduced BubR1 expression in paclitaxel-resistant ovarian carcinoma
cell line SKOV3-TR30. Gynecol Oncol, 2007. 105(1): p. 66-73.
557. Sudo, T., et al., Dependence of paclitaxel sensitivity on a functional spindle assembly checkpoint. Cancer Res, 2004.
64(7): p. 2502-8.
558. Swanton, C., et al., Regulators of mitotic arrest and ceramide metabolism are determinants of sensitivity to paclitaxel
and other chemotherapeutic drugs. Cancer Cell, 2007. 11(6): p. 498-512.
172